Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose versus full-dose intradetrusor botulinum toxin A in children with neurogenic overactive bladder
2010-021265-80Phase 4Completed
- Sponsor
- CHU de Reims
- Start
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of botulinum toxin type A in neurogenic bladder and detrusor hyperreflexia (DH) (2 arms), sponsored by CHU de Reims. Primary endpoints: Urodynamic evaluation and Urinary continence. Started Jul 2010; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
neurogenic bladderdetrusor hyperreflexia (DH)
Beyond the preview
Go deeper on 2010-021265-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021265-80.